Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Crestor Post-NDA Studies Focusing On 40 Mg Dose

Executive Summary

AstraZeneca's ongoing trials of Crestor are focusing on 40 mg as the maximum dose of the cholesterol-lowering drug
Advertisement

Related Content

Crestor 10 mg Dose Is Initial Focus In Canadian Marketing Campaign
Crestor 10 mg Dose Is Initial Focus In Canadian Marketing Campaign
AstraZeneca Launches Crestor In Canada At 15% Discount To Lipitor
AstraZeneca Launches Crestor In Canada At 15% Discount To Lipitor
AstraZeneca Crestor Myopathy Seen At Lower Doses; EU Label Approved
Crestor GALAXY Cardio Study Shoots For The Stars: 71,000 Patients To Recruit
AstraZeneca Crestor Plan: Drop 80 Mg, Submit Lower-Dose Data In Q1
AstraZeneca Crestor is “approvable”
AstraZeneca Crestor 80 Mg Dose Would Have Low Demand, CEO Suggests
Baycol Withdrawal Gives Boost To Pravachol; Will Crestor NDA Be Affected?
Advertisement
UsernamePublicRestriction

Register

PS040209

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel